Nadroparin

Generic Name: Nadroparin

Brand Names: Fraxiparine

Drug Type: Small Molecule

Unique Ingredient Identifier: 1K5KDI46KZ

Background: Nadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. It is derived from porcine sources and has a mean molecular size of 5000 daltons. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.

Indication: Nadroparin is used for prophylaxis of thromboembolic disorders and general surgery in orthopedic surgery, treatment of deep vein thrombosis, prevention of clotting during hemodialysis and treatment of unstable angina and non-Q wave myocardial infarction.

Associated Conditions: Clotting, Deep Vein Thrombosis, Pulmonary Embolism, Unstable Angina Pectoris, Venous Thromboembolism, Non-q wave myocardial infarction, Thromboembolic phenomena

Clinical Trials

Nadroparin Versus TIPS in Cirrhotic Patients With Refractory Asymptomatic PVT

Not Applicable

Not yet recruiting

Conditions: Portal Vein Thrombosis

Interventions: Procedure: TIPS
Drug: Nadroparin

First Posted Date: 2024-03-19

Last Posted Date: 2024-03-21

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 84

Registration Number: NCT06319131

Nadroparin Pharmacokinetics in Different Stages of COVID-19

Completed

Conditions: Mechanical Ventilation
Anticoagulants and Bleeding Disorders
Thrombosis
COVID-19
Nadroparin

Interventions: Drug: Nadroparin

First Posted Date: 2022-11-18

Last Posted Date: 2022-11-18

Lead Sponsor: Medical University of Lublin

Target Recruit Count: 43

Registration Number: NCT05621915

Locations: 🇵🇱
2nd Department of Anesthesiology and Critical Care, Medical University of Lublin, Lublin, Lubelskie, Poland

Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients

Phase 4

Completed

Conditions: Critical Illness

Interventions: Drug: Nadroparin (intravenous Infusion)
Drug: Nadroparin (subcutaneous group)

First Posted Date: 2021-07-29

Last Posted Date: 2021-07-29

Lead Sponsor: Clinique Saint Pierre Ottignies

Target Recruit Count: 60

Registration Number: NCT04982055

Safety of Anticoagulant Therapy After Endoscopic Treatment

Phase 4

Completed

Conditions: Cirrhosis
Portal Vein Thrombosis
Esophageal and Gastric Varices
Anticoagulant-induced Bleeding

Interventions: Drug: nadroparin calcium-warfarin sequential anticoagulation

First Posted Date: 2021-07-26

Last Posted Date: 2022-10-12

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 86

Registration Number: NCT04976543

Locations: 🇨🇳
Department of Gastroenterology,Qilu Hospital,Shandong University, Jinan, Shandong, China

Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine

Phase 2

Recruiting

Conditions: Aneurysmal Subarachnoid Hemorrhage
Delayed Cerebral Ischemia

Interventions: Drug: Nadroparin Injectable Product

First Posted Date: 2020-08-11

Last Posted Date: 2025-01-29

Lead Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Target Recruit Count: 100

Registration Number: NCT04507178

Locations: 🇳🇱
Amsterdam University Medical Centers, Amsterdam, Netherlands

Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis

Phase 4

Completed

Conditions: Liver Cirrhosis
Portal Vein Thrombosis

Interventions: Drug: Nadroparin calcium, warfarin

First Posted Date: 2019-11-22

Last Posted Date: 2021-03-02

Lead Sponsor: Qilu Hospital of Shandong University

Target Recruit Count: 64

Registration Number: NCT04173429

Locations: 🇨🇳
Department of Gastroenterology,Qilu Hospital,Shandong University, Jinan, Shandong, China

Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study

Phase 3

Recruiting

Conditions: May-Thurner Syndrome

Interventions: Drug: Rivaroxaban
Drug: Warfarin
Drug: Nadroparin

First Posted Date: 2019-08-26

Last Posted Date: 2024-04-18

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 224

Registration Number: NCT04067505

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Shanghai 5th People's Hospital, Shanghai, Shanghai, China
🇨🇳
Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China

and more 6 locations

Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters

Phase 3

Recruiting

Conditions: Venous Thromboembolism

Interventions: Drug: Rivaroxaban
Drug: Warfarin
Drug: Nadroparin

First Posted Date: 2019-08-26

Last Posted Date: 2024-04-18

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 200

Registration Number: NCT04066764

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Yantai Yuhuangding Hospital, Yantai, Shangdong, China
🇨🇳
Shanghai 5th People's Hospital, Shanghai, Shanghai, China

and more 4 locations